Summary Hims expects $2.3-2.4 billion in revenue for 2025, with $725 million from weight loss The decision to continue compounding semaglutide (GLP-1s) is controversial given the FDA has declared the shortage over Hims is likely operating within the law and should be able to defend itself against potential FDA actions and third-party litigation On February 24, 2025, Hims & Hers Health, Inc
Ozempic doesn't replace these lifestyle changes
A comprehensive approach to GLP-1 constipation relief should always include electrolyte optimization as a foundational step
For those studying targeted tissue ablation, FTPP offers a more dramatic mechanism
This article is built for teams that operate inside that response: pharma IP counsel modeling secondary patent positions, portfolio managers marking assets to forward curves, generic manufacturers racing for first-filer status, institutional investors sizing revenue at risk, and licensing teams evaluating out-licensing windows before LOE destroys leverage
